This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll more

Move beyond the threshold with Esperoct®

Esperoct® offers patients with haemophilia A a treatment tailored to their needs with higher FVIII activity levels and low ABR allowing them to move beyond the conventional limitations of haemophilia A1-4.
Take life on with Refixia®

Refixia® is an extended half-life recombinant FIX used in routine prophylaxis as well as for bleed control and surgical procedure for HB patients5. Refixia® once weekly prophylaxis gives your patient the confidence to live beyond haemophilia B maintaining high FIX activity level in the non-haemophilia range most of the time5-9.

1.

Esperoct® Summary of Product Characteristics, 2020.

2.

Chowdary P et al. Res Pract Thromb Haemost 2019; 3:542–554.

3.

Giangrande P et al. J Thromb Haemost 2017; 117:252–261.

4.

Giangrande P et al. J Thromb Haemost 2020; 18:5–14

5.

Refixia® Summary of Product Characteristics, 2022.

6.

Collins PW et al. Blood 2014; 124:3880–3886.

7.

Negrier C et al. Haemophilia 2016; 22:507–513.

8.

Tiede A et al. Haemophilia 2017; 23:547–555.

9.

Young G et al. Thromb Res 2016; 141:69–76.

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a healthcare professional can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

This material is intended to be used at the ASH 2023 Congress only

HQ23RFX00045, December 2023